Hartmann C - Search Results

1

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.

Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C, Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C. Ahmadi R, et al. Among authors: hartmann c. J Neurooncol. 2012 Aug;109(1):15-22. doi: 10.1007/s11060-012-0863-y. Epub 2012 Apr 19. J Neurooncol. 2012. PMID: 22528790

2

Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets.

Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Mueller W, et al. Among authors: hartmann c. Am J Pathol. 2002 Jul;161(1):313-9. doi: 10.1016/S0002-9440(10)64183-1. Am J Pathol. 2002. PMID: 12107116 Free PMC article.

3

No preferential loss of paternal 19q alleles in oligodendroglial tumors.

Hartmann C, Mueller W, Lass U, Stockhammer F, von Eckardstein K, Veelken J, Jeuken J, Wick W, von Deimling A. Hartmann C, et al. Ann Neurol. 2003 Aug;54(2):256-8. doi: 10.1002/ana.10649. Ann Neurol. 2003. PMID: 12891681

4

Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma.

Hartmann C, Nümann A, Mueller W, Holtkamp N, Simon M, von Deimling A. Hartmann C, et al. Int J Cancer. 2004 Mar 1;108(6):839-44. doi: 10.1002/ijc.11638. Int J Cancer. 2004. PMID: 14712485

5

No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma.

Tallen G, Kaiser I, Krabbe S, Lass U, Hartmann C, Henze G, Riabowol K, von Deimling A. Tallen G, et al. Among authors: hartmann c. Int J Cancer. 2004 Apr 10;109(3):476-9. doi: 10.1002/ijc.11715. Int J Cancer. 2004. PMID: 14961591

6

Pathology and molecular genetics of oligodendroglial tumors.

Hartmann C, Mueller W, von Deimling A. Hartmann C, et al. J Mol Med (Berl). 2004 Oct;82(10):638-55. doi: 10.1007/s00109-004-0565-9. J Mol Med (Berl). 2004. PMID: 15322700 Review.

7

Estimating cancer survival and clinical outcome based on genetic tumor progression scores.

Rahnenführer J, Beerenwinkel N, Schulz WA, Hartmann C, von Deimling A, Wullich B, Lengauer T. Rahnenführer J, et al. Among authors: hartmann c. Bioinformatics. 2005 May 15;21(10):2438-46. doi: 10.1093/bioinformatics/bti312. Epub 2005 Feb 10. Bioinformatics. 2005. PMID: 15705654

8

Molecular genetic analysis of oligodendroglial tumors.

Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A. Hartmann C, et al. J Neuropathol Exp Neurol. 2005 Jan;64(1):10-4. doi: 10.1093/jnen/64.1.10. J Neuropathol Exp Neurol. 2005. PMID: 15715080 Review.

9

PIK3CA mutations in glioblastoma multiforme.

Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A. Hartmann C, et al. Acta Neuropathol. 2005 Jun;109(6):639-42. doi: 10.1007/s00401-005-1000-1. Epub 2005 May 28. Acta Neuropathol. 2005. PMID: 15924253

10

Oligodendrogliomas: impact of molecular genetics on treatment.

Hartmann C, von Deimling A. Hartmann C, et al. Neurol India. 2005 Jun;53(2):140-8. doi: 10.4103/0028-3886.16394. Neurol India. 2005. PMID: 16010049 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,126 results

Search Page

Filters